(Reuters) - Valeant Pharmaceuticals International Inc is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio, Bloomberg reported, citing people familiar with the matter.
A sale could value Amoun at $700 million to $800 million, Bloomberg reported. (http://bloom.bg/1EXe5PQ)
Valeant was not immediately available for comment.
Should Amoun fail to find a buyer, it may consider an initial public offering in London, the report said.
Amoun could not be immediately reached for comment.